Citations (109)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Anna Kotzeva, Deepali Mittal, Supriya Desai, Davneet Judge & Kunal Samanta. (2023) Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics 26:1, pages 70-83.
Read now
Read now
Naoko Shigeta, Salim Ahmed, Syed Walid Ahmed, Arfan R Afzal, Mahdi Qasqas, Hideyuki Kanda, Yoshihiro Ishikawa & Tanvir C Turin. (2017) Content analysis of Canadian newspapers articles and readers’ comments related to schizophrenia. International Journal of Culture and Mental Health 10:1, pages 75-81.
Read now
Read now
Huey Yi Chong, Siew Li Teoh, David Bin-Chia Wu, Surachai Kotirum, Chiun-Fang Chiou & Nathorn Chaiyakunapruk. (2016) Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment 12, pages 357-373.
Read now
Read now
Amanda L Neil & Vaughan J Carr. (2016) Global economic burden of schizophrenia: letter in response. Neuropsychiatric Disease and Treatment 12, pages 3069-3072.
Read now
Read now
Chiun-Fang Chiou, Bruce CM Wang, Ronald Caldwell, Wesley Furnback, Jung-Sun Lee, Nathan Kothandaraman, Sun Kyoung Lee, Jin Wang & Fan Zhang. (2015) The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia. Neuropsychiatric Disease and Treatment 11, pages 1989-1994.
Read now
Read now
Jing Wu, Xiaoning He, Li Liu, Wenyu Ye, William Montgomery, Haibo Xue & Jeffery S McCombs. (2015) Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China. Neuropsychiatric Disease and Treatment 11, pages 983-990.
Read now
Read now
Richard Williams, Ranjith Chandrasena, Linda Beauclair, Doanh Luong & Annette Lam. (2014) Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. Neuropsychiatric Disease and Treatment 10, pages 417-425.
Read now
Read now
Jean Lachaine, Catherine Beauchemin, Karine Mathurin, Dominique Gilbert & Maud Beillat. (2014) Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. Journal of Medical Economics 17:4, pages 296-304.
Read now
Read now
Rogelio Apiquian, Rodrigo Córdoba & Mario Louzã. (2011) Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatric Disease and Treatment 7, pages 19-26.
Read now
Read now
Deborah Nicholl, Kasem S. Akhras, Joris Diels & Jan Schadrack. (2010) Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Current Medical Research and Opinion 26:4, pages 943-955.
Read now
Read now
Allen
E. Thornton, Hayley Kristinsson, Vanessa
G. DeFreitas & Wendy
Loken Thornton. (2010) The ecological validity of everyday cognition in hospitalized patients with serious mental illness. Journal of Clinical and Experimental Neuropsychology 32:3, pages 299-308.
Read now
Read now
J. M. Olivares, J. Peuskens, J. Pecenak, S. Resseler, A. Jacobs & K. S. Akhras. (2009) Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Current Medical Research and Opinion 25:9, pages 2197-2206.
Read now
Read now
Pierre Chue. (2007) Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric Disease and Treatment 3:1, pages 13-39.
Read now
Read now
Linda Beauclair, Pierre Chue, John McCormick, Fernando Camacho, Annette Lam & Doanh Luong. (2007) Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. Journal of Medical Economics 10:4, pages 427-442.
Read now
Read now
Grant H Skrepnek, Edward P Armstrong, Katie Brookler, John Roper, Beth E Martin, Laurel Karabatsos & Christy Hunter. (2007) Cost analysis of a disease management programme for adult Medicaid clients with schizophrenia. Journal of Medical Economics 10:4, pages 411-426.
Read now
Read now
Articles from other publishers (94)
Maxime Huot‐Lavoie, Charles Desmeules, Olivier Corbeil, Laurent Béchard, Sébastien Brodeur, Anne‐Marie Essiambre, Chantale Thériault, Elizabeth Anderson, Lauryann Bachand, Zain Al‐Aabideen Haider, Amal Abdel‐Baki, Yasser Khazaal, Isabelle Giroux, Marie‐France Demers & Marc‐André Roy. (2023) Impact of gaming disorder on first episode psychosis patients' evolution: Protocol for a multicentered prospective study. Early Intervention in Psychiatry.
Crossref
Crossref
Michael W Best, Sylvia Romanowska, Ying Zhou, Linbo Wang, Talia Leibovitz, Karin A Onno, Shreya Jagtap & Christopher R Bowie. (2023) Efficacy of Remotely Delivered Evidence-Based Psychosocial Treatments for Schizophrenia-Spectrum Disorders: A Series of Systematic Reviews and Meta-Analyses. Schizophrenia Bulletin 49:4, pages 973-986.
Crossref
Crossref
Homa Seyedmirzaei, Saba Katebian, Donya Pourkand, Giulia Cattarinussi, Fabio Sambataro, Paolo Brambilla & Giuseppe Delvecchio. (2023) Effects of COVID-19 pandemic on depression in patients with schizophrenia: A mini-review of the current evidence. Journal of Affective Disorders 332, pages 143-149.
Crossref
Crossref
Dylan T. Gatner, Kevin S. Douglas, Madison F. E. Almond, Stephen D. Hart & P. Randall Kropp. (2022) An Economic Analysis of Crime Costs Associated with Psychopathic Personality Disorder and Violence Risk. Criminal Justice and Behavior 50:5, pages 729-746.
Crossref
Crossref
Sony Subedi, Ni Gusti Ayu Nanditha, Hiwot M Tafessu, Hasan Nathani, Martin St-Jean, Julius Elefante, Thomas L Patterson, William G Honer, Julio S G Montaner & Viviane D Lima. (2023) Healthcare utilisation and costs associated with adherence to antipsychotics among people living with HIV/AIDS and schizophrenia: a population-based cohort study in British Columbia, Canada. BMJ Open 13:4, pages e070680.
Crossref
Crossref
Claire Lin, Xiaoyu Zhang & Huajie Jin. (2022) The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies. PharmacoEconomics 41:2, pages 139-153.
Crossref
Crossref
Andrew J Stewart, Scott B Patten, Kirsten M Fiest, Tyler S Williamson, James P Wick & Paul E Ronksley. (2023) Identifying Unique Subgroups of High-Cost Patients With Schizophrenia: A Population-Based Study Using Latent Class Analysis. Health Services Insights 16.
Crossref
Crossref
Kai On Wong, Scott W. Klarenbach, Karen J. B. Martins, Pierre Chue, Serdar M. Dursun, Mark Snaterse, Alexis Guigue, Helen So, Huong Luu, Khanh Vu & Lawrence Richer. (2022) Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study. BMC Psychiatry 22:1.
Crossref
Crossref
Andrew J. Stewart, Scott B. Patten, Kirsten M. Fiest, Tyler S. Williamson, James P. Wick & Paul E. Ronksley. (2022) 10-Year Trends in Healthcare Spending among Patients with Schizophrenia in Alberta, Canada. The Canadian Journal of Psychiatry 67:9, pages 725-735.
Crossref
Crossref
Джамиля Исмаилова, Билал Асадов Джамиля Исмаилова, Билал Асадов. (2022) ОСОБЕННОСТИ ИЗУЧЕНИЯ ПОТРЕБНОСТЕЙ ПАЦИЕНТОВ С ШИЗОФРЕНИЕЙ И ЧЛЕНОВ ИХ СЕМЕЙ В КОНТЕКСТЕ БИОПСИХОСОЦИАЛЬНОГО ПОДХОДА. The Caucasus-Economic and Social Analysis Journal of Southern Caucasus 49:02, pages 30-35.
Crossref
Crossref
Daniel Mendelson, Élisabeth Thibaudeau, Geneviève Sauvé, Katie M. Lavigne, Christopher R. Bowie, Mahesh Menon, Todd S. Woodward, Martin Lepage & Delphine Raucher-Chéné. (2022) Remote group therapies for cognitive health in schizophrenia-spectrum disorders: Feasible, acceptable, engaging. Schizophrenia Research: Cognition 28, pages 100230.
Crossref
Crossref
Ofer Agid, Gary Remington, Carmen Fung, Natalie M. Nightingale, Marc Duclos & Gregory J. Anger. (2021) Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. The Canadian Journal of Psychiatry 67:3, pages 226-234.
Crossref
Crossref
Tania Lecomte, Jean Addington, Chris Bowie, Martin Lepage, Stéphane Potvin, Jai Shah, Chris Summerville & Phil Tibbo. (2021) The Canadian Network for Research in Schizophrenia and Psychoses: A Nationally Focused Approach to Psychosis and Schizophrenia Research. The Canadian Journal of Psychiatry 67:3, pages 172-175.
Crossref
Crossref
Tarek K. Rajji, David C. Mamo, Jason Holden, Eric Granholm & Benoit H. Mulsant. (2022) Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction. Schizophrenia Research 239, pages 160-167.
Crossref
Crossref
Sean Kidd, Kwame McKenzie, Wei Wang, Sacha Agrawal & Aristotle Voineskos. (2021) Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-Management and Provider Engagement: Protocol for a Feasibility Trial. JMIR Research Protocols 10:1, pages e24736.
Crossref
Crossref
Laurie Pelletier, Sylvain Grignon & Kevin Zemmour. (2021) Outils pédagogiques pour améliorer la relation thérapeutique des psychiatres et résidents en psychiatrie envers les patients souffrant de psychose : revue systématiqueEducational Tools to Improve the Therapeutic Relationship of Psychiatrists and Psychiatric Residents with Patients Suffering from Psychosis: A Systematic Review. Santé mentale au Québec 46:2, pages 417.
Crossref
Crossref
Martin Cloutier, Ameur M. Manceur, Annie Guerin, Myrlene Sanon Aigbogun, Dorothee Oberdhan & Marjolaine Gauthier-Loiselle. (2020) The societal economic burden of autosomal dominant polycystic kidney disease in the United States. BMC Health Services Research 20:1.
Crossref
Crossref
Alexia Polillo, George Foussias, Albert H C Wong, Augustina Ampofo, Vicky Stergiopoulos, Kelly K Anderson, Sarah Bromley, Jessica D'Arcey, Claire de Oliveira, Lillian Duda, Joanna Henderson, Sean Kidd, Paul Kurdyak, Wei Wang, Juveria Zaheer, Aristotle N Voineskos & Nicole Kozloff. (2020) ED to EPI: protocol for a pragmatic randomised controlled trial of an SMS (text) messaging intervention to improve the transition from the emergency department to early psychosis intervention for young people with psychosis. BMJ Open 10:12, pages e042751.
Crossref
Crossref
Justin K. Ellis, Elaine F. Walker & David R. Goldsmith. (2020) Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for Conversion. Frontiers in Psychiatry 11.
Crossref
Crossref
Rowena Jacobs, Lauren Aylott, Ceri Dare, Tim Doran, Simon Gilbody, Maria Goddard, Hugh Gravelle, Nils Gutacker, Panagiotis Kasteridis, Tony Kendrick, Anne Mason, Nigel Rice, Jemimah Ride, Najma Siddiqi & Rachael Williams. (2020) The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study. Health Services and Delivery Research 8:25, pages 1-126.
Crossref
Crossref
Paul D. Hastings, Lisa A. Serbin, William Bukowski, Jonathan L. Helm, Dale M. Stack, Daniel J. Dickson, Jane E. Ledingham & Alex E. Schwartzman. (2019) Predicting psychosis-spectrum diagnoses in adulthood from social behaviors and neighborhood contexts in childhood. Development and Psychopathology 32:2, pages 465-479.
Crossref
Crossref
Rebecca Rodrigues, Adam Beswick & Kelly K. Anderson. (2019) Psychiatric hospitalization following psychosis onset: A retrospective cohort study using health administrative data. Early Intervention in Psychiatry 14:2, pages 235-240.
Crossref
Crossref
Jemimah Ride, Panagiotis Kasteridis, Nils Gutacker, Maria Jose Aragon Aragon & Rowena Jacobs. (2019) Healthcare Costs for People with Serious Mental Illness in England: An Analysis of Costs Across Primary Care, Hospital Care, and Specialist Mental Healthcare. Applied Health Economics and Health Policy 18:2, pages 177-188.
Crossref
Crossref
David R. Goldsmith & Mark Hyman Rapaport. (2020) Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Frontiers in Psychiatry 11.
Crossref
Crossref
S.K. Zyryanov, I.N. Dyakov, A.A. Juperin, D.A. Egorova & E.S. Mosolova. (2020) The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 82.
Crossref
Crossref
Dennis R. Combs, Thomas Bart, Lauren Bennett & Michael R. Basso. 2020. Handbook of Dual Diagnosis. Handbook of Dual Diagnosis
239
249
.
Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx & Ashok Malla. (2019) Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry 19:1.
Crossref
Crossref
Sean A. Kidd, Laura Feldcamp, Amos Adler, Linda Kaleis, Wei Wang, Klara Vichnevetski, Kwame McKenzie & Aristotle Voineskos. (2019) Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: App4Independence (A4i). PLOS ONE 14:7, pages e0219491.
Crossref
Crossref
Magalie Lussier-Valade, Alex Desautels & Roger Godbout. (2020) Troubles psychotiques et troubles du sommeil : revue de la littérature. Santé mentale au Québec 44:2, pages 163-194.
Crossref
Crossref
Meghamala S. Tavaragi & Sushma C.. 2019. Chronic Illness and Long-Term Care. Chronic Illness and Long-Term Care
445
467
.
I. N. Dyakov & S. K. Zyryanov. (2019) Clinical and economic efficiency of treatment with cariprazine in schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:7, pages 69.
Crossref
Crossref
Jamison Pike & Scott D. Grosse. (2018) Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review. Applied Health Economics and Health Policy 16:6, pages 765-778.
Crossref
Crossref
Anika Maraj, Srividya N. IyerJai L. Shah. (2018) Enhancing the Engagement of Immigrant and Ethnocultural Minority Clients in Canadian Early Intervention Services for Psychosis. The Canadian Journal of Psychiatry 63:11, pages 740-747.
Crossref
Crossref
Aleksandra Dutina & Ivana Stašević-Karličić. (2018) Pharmacoeconomic aspects of schizophrenia. Racionalna terapija 10:1, pages 37-41.
Crossref
Crossref
Sheng Chen, April Collins, Kelly Anderson, Kwame McKenzie & Sean Kidd. (2016) Patient Characteristics, Length of Stay, and Functional Improvement for Schizophrenia Spectrum Disorders: A Population Study of Inpatient Care in Ontario 2005 to 2015. The Canadian Journal of Psychiatry 62:12, pages 854-863.
Crossref
Crossref
Philippe D. Vincent, Marie-France Demers, Venessa Doyon-Kemp, Jos?e Duchesneau, Alex Halme & Violaine Masson. (2017) One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophrenia Research 185, pages 96-100.
Crossref
Crossref
Dennis R. Combs & Kim T. Mueser. 2017. Treatments for Psychological Problems and Syndromes. Treatments for Psychological Problems and Syndromes
188
201
.
Meghamala S. Tavaragi & Sushma C.. 2017. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment
164
186
.
Huajie Jin & Iris Mosweu. (2016) The Societal Cost of Schizophrenia: A Systematic Review. PharmacoEconomics 35:1, pages 25-42.
Crossref
Crossref
Yong Wu, Yong-Gang Yao & Xiong-Jian Luo. (2016) SZDB: A Database for Schizophrenia Genetic Research. Schizophrenia Bulletin, pages sbw102.
Crossref
Crossref
Jayanti Bhattacharjee & Hany G El-Sayeh. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jayanti Bhattacharjee & Hany G El-Sayeh. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jayanti Bhattacharjee & Hany G El-Sayeh. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jayanti Bhattacharjee & Hany G El-Sayeh. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Christopher Tsoutsoulas, Benoit H. Mulsant, Sawsan M. Kalache, Sanjeev Kumar, Zaid Ghazala, Aristotle N. Voineskos, Meryl A. Butters, Mahesh Menon & Tarek K. Rajji. (2016) The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. Schizophrenia Research 170:2-3, pages 330-335.
Crossref
Crossref
Lan Gao, Hao Hu, Fei-Li Zhao & Shu-Chuen Li. (2016) Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLOS ONE 11:1, pages e0147169.
Crossref
Crossref
Basant Pradhan & Narsimha R. Pinninti. 2016. Brief Interventions for Psychosis. Brief Interventions for Psychosis
55
87
.
A. George Awad & Lakshmi N. P. Voruganti. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia
175
183
.
Xiaoning He, Jing Wu, Yawen Jiang, Li Liu, Wenyu Ye, Haibo Xue & William Montgomery. (2015) Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China. BMC Health Services Research 15:1.
Crossref
Crossref
Danyael Lutgens, Srividya Iyer, Ridha Joober, Thomas G Brown, Ross Norman, Eric Latimer, Norbert Schmitz, Amal Abdel Baki, Sherezad Abadi & Ashok Malla. (2015) A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: study protocol. BMC Psychiatry 15:1.
Crossref
Crossref
Huali Lin, Ying Lei, Bo Zhang, Zunxiao Dai & Xiaoyun Lu. (2015)
Common variants of
HTR1A
and
SLC6A4
confer the increasing risk of Schizophrenia susceptibility: A population-based association and epistasis analysis
. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 168:8, pages 749-755.
Crossref
Crossref
Solomon J. Lubinga, Byamah B. Mutamba, Angelo Nganizi & Joseph B. Babigumira. (2015) A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. Applied Health Economics and Health Policy 13:5, pages 493-506.
Crossref
Crossref
Farooq Naeem, M. Selim Asmer, Bassam Khoury, David Kingdon & Saeed Farooq. (2015) Acceptance and Commitment Therapy for schizophrenia and related disorders. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Farooq Naeem, Shuo Xiang, Tariq A Munshi, David Kingdon & Saeed Farooq. (2015) Self-help and guided self-help interventions for schizophrenia and related disorders. Cochrane Database of Systematic Reviews.
Crossref
Crossref
S. M. Kalache, B. H. Mulsant, S. J. C. Davies, A. Y. Liu, A. N. Voineskos, M. A. Butters, D. Miranda, M. Menon, R. S. Kern & T. K. Rajji. (2014) The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. Schizophrenia Bulletin 41:2, pages 374-381.
Crossref
Crossref
Roberto Ravasio, Giuseppe Nicolò & Marco Vaggi. (2014) Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2:1, pages GRHTA.5000186.
Crossref
Crossref
Bomin Sun, Wei Liu, Shikun Zhan, Qianqian Hao, Dianyou Li, Yixin Pan, Yongchao Li & Guozhen Lin. 2015. Neurosurgical Treatments for Psychiatric Disorders. Neurosurgical Treatments for Psychiatric Disorders
189
201
.
André Ngamini Ngui, Philippe Apparicio, Marie-Josée Fleury, Jean-Pierre Grégoire, Jocelyne Moisan, Alain Lesage & Alain Vanasse. (2014) Disentangling the influence of neighborhood and individual characteristics on early residential mobility among newly diagnosed patients with schizophrenia: a multilevel analysis. Social Psychiatry and Psychiatric Epidemiology 49:10, pages 1569-1578.
Crossref
Crossref
Teena Willoughby, Royette Tavernier, Chloe Hamza, Paul J.C. Adachi & Marie Good. (2014) The triadic systems model perspective and adolescent risk taking. Brain and Cognition 89, pages 114-115.
Crossref
Crossref
Christina Pataky-Forsyth, Philip Gerretsen & Bruce Pollock. 2014. Handbook of Personalized Medicine. Handbook of Personalized Medicine
341
374
.
Tarek K Rajji, Dielle Miranda & Benoit H Mulsant. (2014) Cognition, Function, and Disability in Patients with Schizophrenia: A Review of Longitudinal Studies. The Canadian Journal of Psychiatry 59:1, pages 13-17.
Crossref
Crossref
Emilio Sacchetti, Antonio Vita, Alberto Siracusano & Wolfgang FleischhackerEmilio Sacchetti & Antonio Vita. 2014. Adherence to Antipsychotics in Schizophrenia. Adherence to Antipsychotics in Schizophrenia
1
84
.
Jinguo Zhai, Xiaofeng Guo, Min Chen, Jingping Zhao & Zhonghua Su. (2013) An investigation of economic costs of schizophrenia in two areas of China. International Journal of Mental Health Systems 7:1.
Crossref
Crossref
Sophie Lauzier, Jean-Pierre Grégoire, Alain Lesage & Jocelyne Moisan. (2013) Community pharmacy loyalty among individuals with schizophrenia. Research in Social and Administrative Pharmacy 9:6, pages 806-816.
Crossref
Crossref
André Ngamini Ngui, Philippe Apparicio, Marie-Josée Fleury, Alain Lesage, Jean-Pierre Grégoire, Jocelyne Moisan & Alain Vanasse. (2013) Spatio-temporal clustering of the incidence of schizophrenia in Quebec, Canada from 2004 to 2007. Spatial and Spatio-temporal Epidemiology 6, pages 37-47.
Crossref
Crossref
Donna J. Lang, Alasdair M. Barr & Ric M. Procyshyn. (2013) Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Current Cardiovascular Risk Reports 7:4, pages 283-287.
Crossref
Crossref
V. M. Goghari, M. Harrow, L. S. Grossman & C. Rosen. (2012) A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychological Medicine 43:06, pages 1151-1160.
Crossref
Crossref
Shannon Bredin, Darren Warburton & Donna Lang. (2013) The Health Benefits and Challenges of Exercise Training in Persons Living with Schizophrenia: A Pilot Study. Brain Sciences 3:4, pages 821-848.
Crossref
Crossref
N. Charrier, K. Chevreul & I. Durand-Zaleski. (2013) Le coût de la schizophrénie : revue de la littérature internationale. L'Encéphale 39, pages S49-S56.
Crossref
Crossref
Fiore Lalla & Larry Arshoff. (2013) A Mental Health Initiative to Enhance Schizophrenia Treatment Efficacy. Healthcare Management Forum 26:1, pages 46-50.
Crossref
Crossref
Tarek K. Rajji, Aristotle N. Voineskos, Meryl A. Butters, Dielle Miranda, Tamara Arenovich, Mahesh Menon, Zahinoor Ismail, Robert S. Kern & Benoit H. Mulsant. (2013) Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: A Study Using the MATRICS Consensus Cognitive Battery. The American Journal of Geriatric Psychiatry 21:2, pages 108-118.
Crossref
Crossref
Ofer Agid, Krysta McDonald, Cynthia Siu, Christopher Tsoutsoulas, Caroline Wass, Robert B. Zipursky, George Foussias & Gary Remington. (2012) Happiness in first-episode schizophrenia. Schizophrenia Research 141:1, pages 98-103.
Crossref
Crossref
David Koczerginski & Lorna Thompson. (2012) Déterminer les tendances et les transitions dans la prise en charge de patients atteints de schizophrénie aux consultations externes des hôpitaux. Healthcare Management Forum 25:3_suppl, pages S65-S70.
Crossref
Crossref
David Koczerginski & Lorna Thompson. (2012) Identifying Trends and Transitions in the Hospital Outpatient Management of Patients with Schizophrenia. Healthcare Management Forum 25:3_suppl, pages S59-S64.
Crossref
Crossref
Kevin Skoblenick & Stefan Everling. (2012) NMDA Antagonist Ketamine Reduces Task Selectivity in Macaque Dorsolateral Prefrontal Neurons and Impairs Performance of Randomly Interleaved Prosaccades and Antisaccades. The Journal of Neuroscience 32:35, pages 12018-12027.
Crossref
Crossref
Bailey A. Dyck, Mattea L. Tan, Ritesh P. Daya, Dipannita Basu, Christal D.R. Sookram, Nancy Thomas & Ram K. Mishra. (2012) Behavioral effects of non-viral mediated RNA interference of synapsin II in the medial prefrontal cortex of the rat. Schizophrenia Research 137:1-3, pages 32-38.
Crossref
Crossref
Helen Kitchen, Diana Rofail, Louise Heron & Pat Sacco. (2012) Cognitive Impairment Associated with Schizophrenia: A Review of the Humanistic Burden. Advances in Therapy 29:2, pages 148-162.
Crossref
Crossref
Cocchi Angelo, Mapelli Vittorio, Meneghelli Anna & Preti Antonio. (2011) Cost-effectiveness of treating first-episode psychosis: five-year follow-up results from an Italian early intervention programme. Early Intervention in Psychiatry 5:3, pages 203-211.
Crossref
Crossref
L. Skalli & L. Nicole. (2011) Programmes pour premiers épisodes psychotiques : une revue systématique de la littérature. L'Encéphale 37, pages S66-S76.
Crossref
Crossref
Catherine L. Ryan, Mark A. Robbins, Meghan T. Smith, Ian C. Gallant, Amber L. Adams-Marriott & Tracy A. Doucette. (2011) Altered social interaction in adult rats following neonatal treatment with domoic acid. Physiology & Behavior 102:3-4, pages 291-295.
Crossref
Crossref
Claudiane Salles Daltio, Jair Jesus Mari & Marcos Bosi Ferraz. (2011) Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. Revista de Saúde Pública 45:1, pages 14-23.
Crossref
Crossref
Iain Kooyman & Elizabeth Walsh. 2010. Schizophrenia. Schizophrenia
644
665
.
John L. Waddington, Colm M. P. O'Tuathaigh & Gary J. Remington. 2010. Schizophrenia. Schizophrenia
483
514
.
Roger S. McIntyre, Lael Cragin, Sonja Sorensen, Huseyin Naci, Tim Baker & Jean-Pascal Roussy. (2010) Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of Evaluation in Clinical Practice 16:4, pages 744-755.
Crossref
Crossref
R. Andrew Tasker, Amber L. Adams-Marriott & Christopher A. Shaw. (2010) New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment. EPMA Journal 1:2, pages 217-227.
Crossref
Crossref
Ronny Bruffaerts, Anke Bonnewyn & Koen Demyttenaere. (2020) The individual and societal effects of non-psychotic serious mental disorders on earnings in Belgium. European Psychiatry 24:4, pages 207-213.
Crossref
Crossref
Maria Geitona, Hara Kousoulakou, Markos Ollandezos, Kostas Athanasakis, Sotiria Papanicolaou & Ioannis Kyriopoulos. (2008) Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. Annals of General Psychiatry 7:1.
Crossref
Crossref
Speranta Avram, Heinz Berner, Adina L. Milac & Peter Wolschann. (2008) Quantitative structure – activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment. Monatshefte für Chemie - Chemical Monthly 139:4, pages 407-426.
Crossref
Crossref
Sung Man ChangSeong-Jin ChoHong Jin JeonBong-Jin HahmHyo Jung LeeJong-Ik ParkMaeng Je Cho. (2008) Economic Burden of Schizophrenia in South Korea. Journal of Korean Medical Science 23:2, pages 167.
Crossref
Crossref
José M Olivares, Alfonso Rodriguez-Martinez, José A Burón, David Alonso-Escolano & Alexander Rodriguez-Morales. (2008) Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia. Applied Health Economics and Health Policy 6:1, pages 41-53.
Crossref
Crossref
Josè M. Olivares, Alfonso Rodriguez-Martinez, Josè A. Buron, David Alonso-Escolano & Alexander Rodriguez-Morales. (2013) Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia. Giornale Italiano di Health Technology Assessment 1:1, pages 39-48.
Crossref
Crossref
RAJIV TANDON, STEVEN D. TARGUM, HENRY A. NASRALLAH & RUTH ROSS. (2006) Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia. Journal of Psychiatric Practice 12:6, pages 348-363.
Crossref
Crossref
Karen DavisonPhD (C), RPhD (C), R. (2006)
Primary Health Care, Mental Health
, And the Dietitian's Role
. Canadian Journal of Dietetic Practice and Research 67:S1, pages S47-S53.
Crossref
Crossref
Juan Oliva-Moreno, Julio López-Bastida, Rubén Osuna-Guerrero, Angel Luis Montejo-González & Beatriz Duque-González. (2006) The costs of schizophrenia in Spain. The European Journal of Health Economics 7:3, pages 179-184.
Crossref
Crossref